The video contains an interview with Professor Claude Wischik, Chairman of TauRx Therapeutics. It is a good explanation of the drug rember, its targets, future development and the upcoming Phase 3 trial. Rember is being touted as a major breakthrough in the treatment of Alzheimer’s disease.
A major breakthrough in the treatment of Alzheimer’s disease was revealed by scientists at the Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD 2008). Their pioneering research points to a new treatment that appears to slow the progress of the disorder by 81% over a year, and could offer hope to millions worldwide. The product – remberTM – is the first drug to act on the tangles associated with alzheimer’s, dementia and other memory disorders.
TauRx Therapeutics is developing a novel treatment based on an entirely new approach which targets the tangles, aggregates of abnormal fibres of tau protein forming inside nerve cells in the brain. These aggregates first destroy nerve cells critical for memory and then destroy neurons in other parts of the brain as the disease progresses.
Patients receiving the study treatment experienced an 81% reduction in cognitive decline over one year, and did not experience a significant decline in their mental function over 19 months. The TauRx brain imaging data also showed that the drug had its biggest effect in the memory critical parts of the brain where the tangle density is highest.
Professor Claude Wischik, Chairman of TauRx Therapeutics and Professor of Psychiatric Geratology and Old Age Psychiatry at the University of Aberdeen’s Institute of Medical Sciences, who led the research, said: “This is an unprecedented result in the treatment of Alzheimer’s disease. We have demonstrated for the first time that it may possible to arrest the progression of this disease by targeting the tangles which are highly correlated with the disease.”
“This is the most significant development in the treatment of the tangles since Alois Alzheimer discovered them in 1907.”